How THC Works: The Neuroscience of Cannabis Intoxication

On a spring afternoon in 1964, Israeli chemist Raphael Mechoulam and his colleague Yechiel Gaoni published a paper in the Journal of the American Chemical Society that would eventually reshape medicine, neuroscience, and drug policy across the globe [1]. They had, for the first time, isolated and fully characterized the structure of delta-9-tetrahydrocannabinol — THC — the primary psychoactive component of cannabis. Mechoulam was 34 years old. He had sourced five kilograms of Lebanese hashish from the Israeli national police, synthesized the compound, and in a now-legendary anecdote, brought THC-laced cake to a lab party before fully understanding its potency. The consequences for his colleagues were illuminating, if unintentional.

Six decades later, THC is one of the most studied psychoactive molecules in pharmacological history. We know with precision how it binds to receptors, which brain regions it affects, why it produces euphoria in some and anxiety in others, how the body metabolizes it, and why its effects diminish with repeated use. What follows is the complete pharmacological picture — from Mechoulam's discovery to the neuroscience of why no two people experience THC quite the same way.

The Discovery of the CB1 Receptor

Mechoulam's 1964 isolation was a structural achievement, but it raised an immediate question: how does THC produce its effects? For 25 years, the mechanism was unknown. Then in 1988, Allyn Howlett and William Devane at St. Louis University demonstrated that THC bound to specific receptor proteins in rat brain tissue with extraordinary selectivity — evidence of a purpose-built molecular target [2]. In 1990, Lisa Matsuda at the National Institute of Mental Health cloned the receptor gene and named it CB1 (cannabinoid receptor type 1). Two years later, Devane and colleagues isolated the brain's own natural ligand for CB1 — an endogenous compound Mechoulam named anandamide, from the Sanskrit word for bliss.

In 1993, Munro et al. at Cambridge University discovered a second receptor subtype — CB2 — expressed predominantly in immune tissues [3]. Together, CB1 and CB2 form the core of the endocannabinoid system, one of the most widely distributed signaling networks in vertebrate biology.

Where CB1 Receptors Live in the Brain

Understanding THC's effects requires understanding the precise neuroanatomical distribution of CB1 receptors. CB1 is not uniformly distributed across the brain — its density varies enormously by region, and this distribution pattern explains both the therapeutic effects and the side effects of THC with remarkable precision.

Basal ganglia: Among the highest concentrations of CB1 in the brain. The basal ganglia regulate motor control and reward circuitry. CB1 activation here contributes to the motor-slowing, body-awareness, and mild sedation characteristic of THC, as well as its interaction with dopamine reward pathways.

Hippocampus: Very high CB1 density. The hippocampus is the brain's primary structure for forming new declarative memories. This is why THC impairs short-term memory encoding — the classic "What were we just talking about?" phenomenon. CB1 activation in the hippocampus suppresses the long-term potentiation (LTP) process that underlies memory formation.

Cerebellum: High CB1 density. The cerebellum coordinates balance and fine motor control, which explains why THC impairs coordination and reaction time — findings with direct relevance to driving safety research.

Prefrontal cortex: Moderate-to-high CB1 density. The prefrontal cortex governs executive function, decision-making, and temporal processing. THC's effects here contribute to altered time perception, difficulty with complex cognitive tasks, and the "thought loops" or racing thoughts some users experience.

Amygdala: Significant CB1 expression. The amygdala processes threat detection and fear responses. At low doses, CB1 activation in the amygdala appears to reduce anxiety by dampening threat-detection signals. At high doses, this system is overwhelmed, and paradoxical anxiety and paranoia can emerge — a dose-dependency with major clinical implications.

Brainstem and spinal cord: CB1 receptors in pain-processing pathways including the periaqueductal gray, dorsal horn of the spinal cord, and dorsal root ganglia underlie THC's analgesic properties. Crucially, CB1 receptors are absent from the brainstem respiratory centers — which explains why, unlike opioids, cannabis does not cause fatal respiratory depression and why there are no recorded THC overdose deaths from pharmacological toxicity alone.

THC as a Partial Agonist: Why This Matters

THC does not activate CB1 receptors the way the brain's own endocannabinoids do. Anandamide and 2-AG are full agonists — when they bind, they produce maximum possible activation of the receptor. THC, by contrast, is a partial agonist [4]. It binds to CB1 with high affinity but produces submaximal receptor activation, even at high concentrations.

This distinction, elucidated by Roger Pertwee and colleagues at the University of Aberdeen, has significant pharmacological consequences. Partial agonists can behave as functional antagonists in tissues where endocannabinoid tone is high — competing with endogenous cannabinoids for receptor binding while producing less activation than the body's own molecules would. This may partly explain why heavy, chronic THC use paradoxically disrupts endocannabinoid signaling rather than amplifying it.

The Dopamine Connection

THC's euphoric effects are mediated primarily through the mesolimbic dopamine system — the brain's core reward circuitry. CB1 receptors are expressed on GABAergic interneurons in the ventral tegmental area (VTA) that normally suppress dopamine neuron firing. When THC activates these CB1 receptors, it inhibits the inhibitory interneurons — a double negative — causing dopamine neurons to fire more freely and release dopamine into the nucleus accumbens (the brain's reward center).

This is the same basic mechanism by which most drugs of abuse, including opioids, nicotine, and alcohol, produce reward. The degree of dopamine release with cannabis is generally considered lower than with harder drugs, which correlates with its comparatively lower addiction liability — though the liability is not zero, as cannabis use disorder affects an estimated 9% of users who try it, rising to 17% among those who start in adolescence.

Anxiety and the Dose Paradox

One of the most clinically relevant aspects of THC pharmacology is its bidirectional effect on anxiety — anxiolytic at low doses, anxiogenic at high doses. This biphasic response is mediated through the amygdala. At low CB1 activation levels, the net effect is reduced threat-signaling and relaxation. As doses increase and CB1 activation becomes more intense, the system shifts: glutamate release in the amygdala increases, producing hyperactivation of threat-detection circuits and the uncomfortable paranoia that many users have experienced from an unexpectedly potent dose.

Individual differences in this dose threshold are substantial. They are influenced by prior exposure history, baseline anxiety levels, the social and environmental context of use (the "set and setting" concept), and critically, genetics — particularly variation in the CNR1 gene encoding the CB1 receptor itself.

Genetic Variation in CNR1

The CNR1 gene contains multiple single nucleotide polymorphisms (SNPs) that alter CB1 receptor expression levels and coupling efficiency. Studies have associated specific CNR1 variants with differential susceptibility to cannabis-induced anxiety, psychosis risk in vulnerable individuals, and the likelihood of developing cannabis dependence. This genetic variability is a major reason why two people can use the same amount of the same cannabis product and have entirely different experiences — from blissful relaxation to acute anxiety.

Tolerance: How the Brain Adapts

Regular THC use produces rapid and pronounced pharmacological tolerance. The mechanism is receptor downregulation and desensitization: with repeated CB1 activation, receptor proteins are internalized into the cell interior (reducing surface density) and become progressively less responsive to activation. Brain imaging studies using PET scanning have demonstrated 20% reductions in CB1 receptor density in the cerebral cortex of heavy daily users compared to non-users — a reduction that partially reverses after approximately four weeks of abstinence.

This tolerance mechanism explains why long-term heavy users often report that cannabis "doesn't work the way it used to" — their endocannabinoid systems have physiologically adapted to compensate for chronic exogenous stimulation. It also provides the neurobiological basis for cannabis withdrawal syndrome: when a heavy user abruptly stops, the downregulated endocannabinoid system is suddenly undersupported, producing irritability, anxiety, sleep disturbance, and appetite changes that can last 1–3 weeks.

Metabolism: THC's Journey Through the Body

After inhalation, THC reaches peak blood concentrations within minutes and rapidly distributes to the brain due to its high lipophilicity. In the liver, cytochrome P450 enzymes — primarily CYP2C9 and CYP3A4 — metabolize THC to 11-hydroxy-THC (11-OH-THC), a metabolite that is itself psychoactive and crosses the blood-brain barrier even more readily than THC. This is why oral cannabis (edibles) can feel more potent than inhaled cannabis: the digestive route produces higher relative concentrations of 11-OH-THC. 11-OH-THC is then further metabolized to 11-nor-9-carboxy-THC (THC-COOH), a non-psychoactive metabolite that is excreted in urine and forms the basis of standard drug tests.

The pharmacology of THC is a story of elegant evolutionary accident: a plant compound that happens to fit receptors designed for the brain's own signaling molecules, producing effects ranging from analgesia to euphoria to paranoia depending on dose, genetics, and context. Understanding this pharmacology is not merely academic — it is the foundation for rational medical use, informed recreational decisions, and the development of next-generation cannabinoid therapeutics designed to deliver therapeutic benefits while minimizing the adverse effects that have complicated cannabis medicine since its earliest trials.